Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasma cell dyscrasias: current status.

R A Kyle1, P A Greipp

  • 1Mayo Medical School, Mayo Clinic, Rochester, Minnesota.

Critical Reviews in Oncology/Hematology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical mythology: Apollo.

Mayo Clinic proceedings·1992
Same author

Amyloidosis. Introduction and overview.

Journal of internal medicine·1992
Same author

Primary systemic amyloidosis.

Journal of internal medicine·1992
Same author

Wladyslaw Bieganski--father of modern Polish medicine.

Mayo Clinic proceedings·1992
Same author

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.

Archives of internal medicine·1992
Same author

Medical mythology: Hera (Juno).

Mayo Clinic proceedings·1992
Same journal

Liquid biopsy for early cancer detection in hereditary cancer syndromes: current evidence.

Critical reviews in oncology/hematology·2026
Same journal

Estrobolome and the Endocrine-Microbiome Axis in Breast and Endometrial Carcinogenesis.

Critical reviews in oncology/hematology·2026
Same journal

Remodeling the immune microenvironment: Engineering IL-2 variants to overcome clinical bottlenecks in PD-1 inhibitor plus chemotherapy.

Critical reviews in oncology/hematology·2026
Same journal

Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management.

Critical reviews in oncology/hematology·2026
Same journal

DNA polymerase epsilon catalytic subunit (POLE) in cancer: Implications for tumor biology and therapeutic strategies - A comprehensive review.

Critical reviews in oncology/hematology·2026
Same journal

Long non-coding RNAs in triple-negative breast cancer: emerging drivers of tumor biology, prognosis, and drug resistance.

Critical reviews in oncology/hematology·2026
See all related articles

This review covers monoclonal gammopathies, including multiple myeloma and Waldenström's macroglobulinemia. It details diagnosis, management, and variant forms, offering insights into future treatment strategies for these plasma cell dyscrasias.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Pathology

Background:

  • Monoclonal gammopathies are a group of plasma cell dyscrasias characterized by the production of a monoclonal protein.
  • Accurate diagnosis and management are crucial for patient outcomes.

Purpose of the Study:

  • To provide a comprehensive review of the current status of monoclonal gammopathies.
  • To discuss the diagnosis, clinical and laboratory findings, and management of multiple myeloma and its variants.
  • To cover Waldenström's macroglobulinemia, heavy-chain diseases, and monoclonal gammopathy of undetermined significance.

Main Methods:

  • Literature review of current status, diagnosis, and management of monoclonal gammopathies.
  • Discussion of clinical and laboratory findings for multiple myeloma and related disorders.

Related Experiment Videos

  • Overview of variant forms and future treatment approaches for myeloma.

    • Main Results:

    • The review details the recognition of monoclonal proteins in serum and urine.
    • Clinical and laboratory findings, management strategies, and future treatment options for multiple myeloma are addressed.
    • Variant forms of multiple myeloma, Waldenström's macroglobulinemia, heavy-chain diseases, and monoclonal gammopathy of undetermined significance are reviewed.

    Conclusions:

    • Effective management of monoclonal gammopathies relies on accurate diagnosis and understanding of disease variants.
    • This review provides a consolidated resource for clinicians and researchers in the field of plasma cell dyscrasias.
    • Further research into novel treatment strategies holds promise for improving outcomes in multiple myeloma and related disorders.